Clinical Trial Update: Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating immunogene-modified T (IgT) cells for glioblastoma multiforme; currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• IgT cells (Immunogene-modified T cells)

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Glioblastoma Multiforme of Brain, Brain Cancer | Phase 1 | Status: ENROLLING_BY_INVITATION